TABLE 2.
Utility Scores and Importance Assigned to Each Attribute and Level
| Utility Estimation (SE) | Importance (Relative) | Importance (Averaged) | |
|---|---|---|---|
| Cognition | |||
| No cognitive impairment | 1.245 (0.040) | 38.6% | 32.7% |
| Cognitive impairment | −1.245 (0.040) | ||
| Disease progression | |||
| No progression in 2 y | 1.133 (0.040) | 35.2% | 31.7% |
| Progression in 2 y | −1.133 (0.040) | ||
| Safety and nurse monitoring | |||
| Infrequent but severe AE plus monitoring 1–2 times a month | −0.434 (0.040) | 13.5% | 14.2% |
| Frequent but mild-moderate AE plus monitoring every 3–6 mo | 0.434 (0.040) | ||
| Route of administration | |||
| Self-administered | 0.240 (0.040) | 7.4% | 10.0% |
| Hospital administration | −0.240 (0.040) | ||
| Frequency of administration | |||
| At least twice a month | −0.143 (0.053) | 5.3% | 11.4% |
| Monthly | −0.056 (0.062) | ||
| Every 6 mo | 0.199 (0.062) |
Abbreviation: AE, adverse effect.
Positive values indicate a greater preference for an attribute.